Latest research on Tenofovir

Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread®, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV-infected people. [Wikipedia] In vivo tenofovir disoproxil fumarate is converted to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate.

Tenofovir interactions

In addition, many antiretrovirals (e.g. rilpivirine, Efavirenz, Tenofovir, elvitegravir and boosted protease inhibitors) are ingested with specific recommendations for food intake, which may be problematic on commercial flights when meal times are fixed. [source, 2016]
Although MECs for NRTIs are not established, the pharmacokinetic parameters of the active intracellular metabolites of Tenofovir and Emtricitabine have been established in one tail study, where both were found to have long terminal half-lives of 164 and 39 h, respectively [21]. [source, 2016]
Nucleoside/nucleotide analogs (NUCs) provide one of the currently available therapies for the management of CHB, including Lamivudine (LAM), adefovir (ADV), telbivudine, Entecavir (ETV) and Tenofovir (TDF) (4). [source, 2016]
Antiretroviral pre-exposure prophylaxis (PrEP) with daily oral Emtricitabine and Tenofovir disoproxil fumarate (FTC/TDF) prevents acquisition of HIV infection in adults1–4 and is recommended by the Centers for Disease Control and Prevention (CDC) in the United States as part of a comprehensive package of preventative measures for individuals at substantial risk of HIV acquisition. [source, 2016]
These guidelines recommended a preferred first-line treatment with a combination of Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC) or Emtricitabine (FTC) and Efavirenz (EFV), with second-line treatment using two nucleoside analogues and a boosted protease inhibitor (PI) [1]. [source, 2016]
TAF is a prodrug of Tenofovir, which is boosted significantly by either Ritonavir or cobicistat. [source, 2016]
There may be no clinically significant safety advantage of TAF 25 mg once daily over Tenofovir 300 mg, in the absence of cobicistat or Ritonavir. [source, 2016]
Especially in those with decompensated liver disease, undergoing immunosuppressive treatment or with contraindications, and those unwilling to receive Peg-IFN, Entecavir or Tenofovir is the only therapeutic options in patients [4]. [source, 2016]
The first-line regimen was preferably a fixed-dose combination of Tenofovir disoproxil fumarate (TDF) 300 mg and Emtricitabine (FTC) 250 mg (Truvada®, Gilead) plus Efavirenz (EFV) 600 mg (Stocrin®, MSD). [source, 2016]
Recently raltegravir, an integrase inhibitor, has been estimated to have efficacy 0.94 in a combination therapy including Emtricitabine and Tenofovir disoproxil fumarate, and 0.997 during monotherapy [41]. [source, 2016]